"Access" landscape for Viral Hepatitis

"Access" landscape for Viral Hepatitis

Shaping knowledge to effect change 

Improving access to diagnostics and medicines will be essential to achieving the elimination of viral hepatitis by 2030. Currently 95% of those living with viral hepatitis are unaware they have the disease and of those that are aware less than 1% access treatment. If we are to reach the goal of 90% of people being aware of their illness and 80% of people treated by 2030, as set out in the Global Health Sector Strategy on Viral Hepatitis, much needs to be done.

Civil society have a key role to play in this through advocating for improved access but in order to ensure that any advocacy efforts are effective and sustainable it is important to first understand the issues in this area.

This resource hub brings together a wide range of resources specifically on access to medicines and diagnostics to help build knowledge in this area.

 

 

WHA Resources

Webinar – An Introduction to Access to Diagnostics

Diagnostic tests are the foundation of disease control and elimination and this webinar gives an introduction to the topics while touching on some of the challenges faced.

Watch here.

The slides for this webinar are also available.

Webinar – An Introduction to Access to Medicines

With effective treatments available for hepatitis B and an increasing number of curative medicines for hepatitis C, access to these medicines is an increasingly important issue. This webinar explores some of the barriers to access and how they are being overcome.

Watch here.

The slides for this webinar are also available.

Webinar – An Introduction to Access to Generic Hepatitis C Medicines

This webinar explores the different ways in which people and countries are accessing generic hepatitis C medicines. It introduces the newly released MedsPaL, from the Medicines Patent Pool, and the role that buyers’ clubs are playing in helping people to access safe and effective generic medicines.

Watch here.

The slides for this webinar are also available.

Document – Access letter

At the World Hepatitis Summit 2015 the global hepatitis community signed an open letter calling for access to life-saving hepatitis drugs. A number of actions were set out for both governments and pharmaceutical companies.

Read here.

Webinar - Sensitivity and Specificity

This short webinar delivered by Dr Greg Martin, explains the difference between sensitivity and specificity in diagnostic tests. A useful tool for those who wish to learn more about diagnostic tests.

Watch here.

Webinar - This Week in Global Health

This Week in Global Health is a webinar series chaired by Dr Greg Martin which takes an overall public health view to explore in greater detail some of the issues around access to medicines.

Watch: Part I: Introduction - Access to Medicines

Watch: Part II: The R&D Gap

Watch: Part III: Intellectual Property

Watch: Part IV: Working in “Access to Medicines”

Website – FIND

FIND diagnostics are working with partners to create better tests to more easily diagnose and monitor HCV.

Learn more here.

Website - Medicines Patent Pool

MPP is a United-Nations backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments. They achieve this by working with other stakeholders to license medicines and so encourage generic manufacture in low- and middle-income countries.

Learn more here.

Website - MedsPaL

This initiative from the Medicines Patent Pool, which was discussed in the webinar ‘An Introduction to Access to Generic Hepatitis C medicines’ now includes information on HCV for the first time. The database, which is searchable, provides information on patents and licenses for generic production, making it easy to determine where generic hepatitis C medicines are available within a country and the means by which they have been made available.

Learn more here.

Website - Amfar TreatAsia

TreatAsia is a network of clinics, hospitals, research institutions and civil society organisations working together to ensure the safe and effective delivery of HIV treatment to both children and adults in the Asia-Pacific region. Through their work with co-infection they have developed a wide range of materials on hepatitis C including factsheets on the WHO guidelines for treatment, treatment snapshots, issue briefs, videos and patient materials.

Learn more here.

Website - Changing Intellectual Property Rules for Access to Medicines

This website gives an easy to understand explanation of the role that patents play in access to medicines and ways in which the barriers they pose can be overcome. It is a useful resource for anyone wanting to know more about patents and intellectual property in regards to access.

Learn more here.

Website – UNITAID

UNITAID takes game-changing ideas and turns them into practical solutions to help accelerate the end of HIV/AIDS, TB and malaria. In 2013 they specifically identified HCV and other HIV co-infections as a target for market shaping interventions and since then they have invested significantly in HCV.

Learn more here.

Website - Clinton Health Access Initiative (CHAI)

The Clinton Health Access Initiative was founded in 2002 with the goal of helping to save the lives of millions living with HIV/AIDS in the developing world. They now deliver programmes on access to medicines, health financing and vaccines and have started to work on projects with a hepatitis C focus.

Learn more here.

Report - General information on WHO prequalification of in vitro diagnostics

The WHO prequalification of diagnostics programme aims to promote and facilitate access to safe, appropriate and affordable diagnostics.

Read more here.

Further details on WHO prequalification programme can be found on the UNITAID website here.

A list of the WHO prequalified in vitro diagnostic products can be found here.

Report - The Global Health Sector Strategy on Viral Hepatitis: 2016 – 2021

The first ever global health sector strategy focusing on viral hepatitis. This report sets out the steps that countries need to take in order to achieve the elimination of viral hepatitis.

Read here.

Report - Global report on Access to Hepatitis C Treatments: Focus on overcoming barriers

This report from the World Health Organization shows how political will, civil society advocacy and pricing negotiations are helping to overcome some of the barriers faced in accessing hepatitis C medicines. Profiling 13 different countries, the report highlights a number of different approaches which makes this a useful starting point for increasing your knowledge on developments in this area.

Read here.

Report - Global report on Access to Hepatitis C Treatments: Focus on overcoming barriers

This report from the World Health Organization shows how political will, civil society advocacy and pricing negotiations are helping to overcome some of the barriers faced in accessing hepatitis C medicines. Profiling 13 different countries, the report highlights a number of different approaches which makes this a useful starting point for increasing your knowledge on developments in this area.

Read here.